newsfilter
← Earnings
Earnings Releases·

Prime Medicine — Third Quarter 2026 Earnings Summary

Prime Medicine dosed the first patient in its global Phase 1/2 clinical trial for PM577a, an in vivo Prime Editing therapy for Wilson disease, with initial data expected in 2027. The company received FDA clearance for its Investigational New Drug application for PM647 to treat Alpha-1 Antitrypsin Deficiency, also anticipating initial clinical data in 2027. Prime Medicine plans to submit a Biologics License Application for PM359 in Chronic Granulomatous Disease during the first half of 2027. In November 2026, the company raised $143.7 million in gross proceeds from a public offering, bringing its pro-forma cash position to approximately $209.5 million to fund operations through 2027.

Company
PRIME MEDICINE INC
Sector
Healthcare
Industry
Biotechnology